X

Hematologic Malignancies

Hematologic Malignancies

Blood Cancer Patients With COVID-19 Fare Better With Convalescent Plasma

A large, retrospective, multicenter study indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients...

Oncology Times - Latest Articles
07/05/2021
Understanding Tolerance for Imatinib Nonadherence Among CML Patients

New analyses from the ADAGIO study presented at the ASCO 2021 Annual Meeting challenge the tolerance for nonadherence to imatinib among patients with chronic myeloid leukemia.

Oncology Times - Latest Articles
07/05/2021
Recovery of Gonadal Function With PET-Adapted Regimen for Advanced Hodgkin Lymphoma

Demeestere et al find that patients with advanced Hodgkin lymphoma receiving a PET-adapted regimen have a reduced risk of gonadal dysfunction vs standard CT.

The ASCO Post
07/06/2021

HNRNPH1 Is a Novel Regulator Of Cellular Proliferation and Disease Progression in Chronic Myeloid Leukemia

In the present study, investigators reveal that HNRNPH1 expression level is upregulated in CML patients and cell lines.

Frontiers in Oncology
07/06/2021
Toxicities of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Older Patients With Lymphoma

Cardiovascular toxicities are higher in older patients, but nonrelapse mortality at 100 days and 1 year is comparable to younger patients.

Blood Advances
06/21/2021
Brexucabtagene Autoleucel in Adults With Relapsed or Refractory B-Cell ALL: ZUMA-3

The pivotal phase II ZUMA-3 trial has shown a high rate of complete remission with the autologous anti-CD19 CAR T-cell therapy brexucabtagene autoleucel in adults with R/R B-cell acute lymphoblasti

The ASCO Post
06/22/2021
Prolonged COVID-19 Common Among Patients With Lymphoma

Patients with B-cell non-Hodgkin lymphoma who are hospitalized for COVID-19 are at high risk of developing prolonged COVID-19.

Medscape
06/17/2021
Luspatercept Benefit Also in Non-Transfusion-Dependent Thalassemia

The first-in-class erythroid maturation agent luspatercept is already approved for the treatment of anemia in adult patients with beta thalassemia who require red blood cell transfusions.

Medscape
06/13/2021
Addition of Copanlisib to Rituximab Improves Progression-Free Survival in Relapsed Indolent Non-Hodgkin Lymphoma

Dr Matasar and colleagues report the phase III CHRONOS-3 trial has shown that the addition of the pan-class I PI3K inhibitor copanlisib to rituximab significantly improves PFS vs rituximab alone...

The ASCO Post
06/11/2021
Copanlisib Combination Cuts Lymphoma Progression by Nearly Half

Combining the pathway inhibitor copanlisib with rituximab reduces disease progression or death by almost one-half in patients with relapsed non-Hodgkin lymphoma.

Oncology Times - Latest Articles
05/20/2021
PET-Guided eBEACOPP Treatment of Advanced-Stage Hodgkin lymphoma (HD18): Follow-up Analysis of an International, Open-Label, Randomized, Phase 3 Trial

The German Hodgkin Study Group's HD18 trial establishes the safety and efficacy of PET-guided eBEACOPP for the treatment of advanced-stage Hodgkin lymphoma.

The Lancet Hematology
06/01/2021
A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Study investigators report the clinical results and the pharmacokinetics of bispecific CD19/22 CAR T in patients with R/R B-NHL.

Frontiers in Oncology
05/25/2021
Cellular Therapies Hold Promise in Myeloid Malignancies

A recent spate of approvals of targeted treatments, such as FLT3 and IDH1/2 inhibitors for acute myeloid leukemia, introduce major changes in the treatment of myeloid malignancies. 

ASH Clinical News
05/01/2021
High- and Low-Dose Rivaroxaban Versus Aspirin for Women With VTE and Heavy Menstrual Bleeding

Results of a substudy published in Research and Practice in Thrombosis and Haemostasis suggest there is no statistically significant difference in menstrual hemorrhage in patients with VTE

ASH Clinical News
05/01/2021
Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Early-Stage Unfavorable-Risk Hodgkin Lymphoma

Kumar et al find that the combination of brentuximab vedotin with AVD is highly active in patients with newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma and may permit the reduction.

The ASCO Post
05/03/2021
Study Finds Tranexamic Acid Unable to Prevent Bleeding in Patients With Hematologic Malignancies

In the first trial to evaluate prophylactic antifibrinolytic therapy in patients with hematologic malignancies, tranexamic acid failed to reduce bleeding or the need for transfusion vs placebo. 

The ASCO Post
04/25/2021
Small Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

Bispecific anti-CD19/CD20 CAR T-cell therapy was well tolerated and showed signs of clinical efficacy in patients with relapsed/refractory B-cell lymphoma, according to phase I clinical trial data.

The ASCO Post
04/12/2021
Burkitt Lymphoma: An International Prognostic Index

A global collaborative effort has led to the development and validation of a novel prognostic index specific for Burkitt lymphoma to aid risk stratification, interpretation of clinical trials...

Oncology Times - Latest Articles
04/05/2021
COVID-19 Vaccine Failure in Patients With Blood Cancers

COVID vaccines do not work well for patients with hematologic malignancies, new data suggest.

Medscape
04/13/2021
Rivaroxaban May Be Clinically Superior to LMWH in Patients With Cancer-Associated Thrombosis

Among patients with cancer-associated thrombosis, rivaroxaban may be superior to low-molecular-weight heparin for reducing all-cause mortality, although additional study is necessary...

Cancer Therapy Advisor
04/13/2021
Lymphoma Patients at Higher Risk of Death When Diagnosed With COVID-19

According to a retrospective study, lymphoma patients admitted to the hospital with severe COVID-19 and treated with B-cell depleting immunotherapy within the previous 12 months have nearly twice..

Oncology Times - Latest Articles
04/05/2021
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331

COG AALL0331 tests whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the CCR rate in a low-risk subset of children with standard-risk B-ALL.

Journal of Clinical Oncology
03/19/2021
DNA Methylation and Cancer Incidence: Lymphatic–Hematopoietic versus Solid Cancers in the Strong Heart Study

This study evaluates the association of blood DNA methylation with lymphatic–hematopoietic cancers and, for comparison, with solid cancers.

Clinical Epigenetics
02/25/2021
Research Minute: The Latest Hematology/Oncology Research

This article takes a deeper look into the most recent developments in CML research and treatment. 

Oncology Times - Latest Articles
02/20/2021
New ASH Guidelines: VTE Prevention and Treatment in Cancer Patients

New ASH guidelines "strongly recommend" using no thromboprophylaxis over using parenteral thromboprophylaxis in ambulatory patients receiving cancer CT who have low VTE risk.

Medscape
03/03/2021
Management of Patients With Multiple Myeloma Beyond the Clinical-Trial Setting: Understanding the Balance Between Efficacy, Safety and Tolerability, and Quality of Life

This review assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience.

Blood Cancer Journal
02/18/2021
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions

Although the emerging roles of precision medicine and personalized medicine in hematology and oncology are clearly visible, several questions remain.

Hemasphere
02/17/2021
Assessment and Management of Cardiotoxicity in Hematologic Malignancies

The most studied drugs associated with cardiotoxicity are anthracyclines, but many new agents have demonstrated unexpected cardiotoxic effect, including those currently used in MM treatment...

Disease Markers
02/03/2021
CD8 T Cells Compensate for Impaired Humoral Immunity in COVID-19 Patients With Hematologic Cancer

These observations have important implications for cancer and COVID-19-directed treatments, immunosuppressive therapies, and for understanding the role of B and T cells in acute COVID-19.

02/02/2021
Cancer Survivorship in Hematologic Malignancies: Lifestyle Changes After Diagnosis

There is a paucity of data regarding changes made after a diagnosis of a hematologic malignancy.

Cancer medicine journal
02/02/2021
Kinase Inhibitors Developed for Treatment of Hematologic Malignancies: Implications for Immune Modulation in COVID-19

Based on in vitro and clinical observations, this study deciphers the impact of the main TKIs approved or in late-stage development for the treatment of hematological malignancies, including...

Blood Advances
02/09/2021
Degradation of BRD4—A Promising Treatment Approach Not Only for Hematologic But Also for Solid Cancer

Bromodomain and extra-terminal proteins are epigenetic readers that regulate gene expression and promote cancer evolution. 

02/01/2021
Hematopoietic Stem Cell Niche During Homeostasis, Malignancy, and Bone Marrow Transplantation

This study discusses how different components of the bone marrow niche, particularly non-hematopoietic and hematopoietic cells, regulate normal hematopoiesis, and...

01/22/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834